Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications
Our findings demonstrate that PDGFRA overexpression mediates lenvatinib resistance in HCC and that targeting PDGFRA with avapritinib, surmounts this resistance. Furthermore, the PTEN/AKT/GSK-3β/β-catenin pathway was implicated in lenvatinib resistance, providing a potential therapeutic strategy for HCC patients displaying lenvatinib resistance. Further clinical studies are warranted to validate these findings and to explore the clinical application of PDGFRA-targeted therapies in HCC treatment.
Authors
- Niangmei Cheng
- Yehuda G. Assaraf (ORCID: https://orcid.org/0000-0001-6692-8221)
- Xiaoyuan Zheng
- Xin Qi (ORCID: https://orcid.org/0000-0001-7553-7943)
- Yang Zhou (ORCID: https://orcid.org/0000-0002-6967-421X)
- Bixing Zhao (ORCID: https://orcid.org/0000-0002-0055-3989)
- Yongyi Zeng (ORCID: https://orcid.org/0000-0001-8823-698X)
- Qiuyu Zhuang (ORCID: https://orcid.org/0000-0002-2200-5641)
- Xiaolong Liu (ORCID: https://orcid.org/0000-0003-1236-1332)
- Fei Wang (ORCID: https://orcid.org/0000-0001-8908-5618)
- Chen Geng (ORCID: https://orcid.org/0000-0003-4008-6833)
- Xiangzhi Zhang (ORCID: https://orcid.org/0000-0003-2223-2761)
- Yingchao Wang (ORCID: https://orcid.org/0000-0002-3847-7977)
Institutions
- Fujian Medical University (CN)
- Mengchao Hepatobiliary Hospital (CN)
- Fuzhou University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1186/s13046-025-03386-8
- Citations
- 6
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 7.93
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province